MedRx Co., Ltd (TSE:4586) announced a private placement of 3,150,000 units of series 15 warrants at an issue price of ¥0.38 per warrant for gross proceeds of ¥1,197,000 on November 15, 2019. The company has signed agreement with the investor. The transaction will include participation from Evo Fund, a fund managed by Evolution Capital Management, LLC. The warrants are exercisable into common shares at an exercise price of ¥338.38 and will receive proceeds of ¥1,065,897,000 post exercise. The warrant exercise period is from December 2019 to December 2020. The transaction has been approved by the board of directors and is expected to close on December 9, 2019.